CN104800187B - A kind of Alfacalcidol soft capsule and preparation method thereof - Google Patents
A kind of Alfacalcidol soft capsule and preparation method thereof Download PDFInfo
- Publication number
- CN104800187B CN104800187B CN201510191507.4A CN201510191507A CN104800187B CN 104800187 B CN104800187 B CN 104800187B CN 201510191507 A CN201510191507 A CN 201510191507A CN 104800187 B CN104800187 B CN 104800187B
- Authority
- CN
- China
- Prior art keywords
- parts
- soft capsule
- alfacalcidol
- macrogol
- accelerator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 title claims abstract description 92
- 229960002535 alfacalcidol Drugs 0.000 title claims abstract description 92
- 239000007901 soft capsule Substances 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 44
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960003511 macrogol Drugs 0.000 claims abstract description 23
- 235000011187 glycerol Nutrition 0.000 claims abstract description 22
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 19
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 19
- 239000002562 thickening agent Substances 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 13
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 18
- 239000011159 matrix material Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 11
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 10
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- 235000004515 gallic acid Nutrition 0.000 claims description 10
- 229940074391 gallic acid Drugs 0.000 claims description 10
- 235000010413 sodium alginate Nutrition 0.000 claims description 10
- 239000000661 sodium alginate Substances 0.000 claims description 10
- 229940005550 sodium alginate Drugs 0.000 claims description 10
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 10
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 10
- 235000010384 tocopherol Nutrition 0.000 claims description 10
- 229960001295 tocopherol Drugs 0.000 claims description 10
- 229930003799 tocopherol Natural products 0.000 claims description 10
- 239000011732 tocopherol Substances 0.000 claims description 10
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 238000005096 rolling process Methods 0.000 claims description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229940101006 anhydrous sodium sulfite Drugs 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 3
- 229940043264 dodecyl sulfate Drugs 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 3
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 claims description 2
- 239000004283 Sodium sorbate Substances 0.000 claims description 2
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 claims description 2
- 235000019250 sodium sorbate Nutrition 0.000 claims description 2
- 229960001777 castor oil Drugs 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 238000001035 drying Methods 0.000 description 11
- 238000005406 washing Methods 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010018873 Haemoconcentration Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000004513 sizing Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940085809 menthol 8 mg Drugs 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 229940080927 menthol 10 mg Drugs 0.000 description 1
- 229940033163 menthol 6 mg Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- -1 now Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of Alfacalcidol soft capsule and preparation method thereof.The content of the soft capsule is prepared from by the following each component of parts by weight：35~50 parts of Alfacalcidol, 15~20 parts of glycerine, 20~40 parts of Macrogol 4000,10~20 parts of Macrogol 6000,10~20 parts of accelerator, 45~57 parts of thickener, 30~60 parts of antioxidant.The present invention improves the content of active component in the formulation, reduces the dose of medicine；By adding specific composition glycerine, Macrogol 4000, Macrogol 6000, the stability and bioavilability of the soft capsule are effectively increased；The formulation of existing Alfacalcidol preparation is successfully changed, Alfacalcidol is preferably taken absorption by patient.
Description
Technical field
The invention belongs to field of medicine preparations, and in particular to a kind of Alfacalcidol soft capsule and preparation method thereof.
Background technology
Alfacalcidol plays regulation calcium, the balanced action of phosphorus in human body, and can increase the absorption of calcium and phosphorus in enteron aisle, drops
Parathyroid hormone level in low blood plasma, and improve postmenopausal women and cause osteoporosis using hormone medicine.It is applied to
Rickets that osteoporosis and a variety of causes are caused, malacosteon.
There is the disintegration defect that result of extraction is poor, bioavilability is low in existing Alfacalcidol oral formulations, influence it
Therapeutic effect clinically, has much room for improvement.And when long-term, high-dose takes Alfacalcidol or patient with renal damage
It is likely to occur the hypercalcemia signs such as nausea, giddy, constipation, apocleisis, vomiting, stomachache.Alfacalcidol soft capsule is in prior art
In do not report, reason is that its bioavilability is low, it is impossible to steadily in the long term exist.
The content of the invention
The technical problem to be solved in the present invention overcomes existing defect high, stable there is provided a kind of bioavilability
Alfacalcidol soft capsule, and the soft capsule preparation method.
It is an object of the present invention to provide a kind of Alfacalcidol soft capsule, the content of the soft capsule is by parts by weight
Following each component is prepared from：
35~50 parts of Alfacalcidol
15~20 parts of glycerine
20~40 parts of Macrogol 4000
10~20 parts of Macrogol 6000
10~20 parts of accelerator
45~57 parts of thickener
30~60 parts of antioxidant.
Preferably scheme, described Alfacalcidol soft capsule, the content of the soft capsule is as follows by parts by weight
Each component be prepared from：
40~45 parts of Alfacalcidol
17~20 parts of glycerine
25~38 parts of Macrogol 4000
13~18 parts of Macrogol 6000
13~17 parts of accelerator
48~54 parts of thickener
34~50 parts of antioxidant.
As more preferably scheme, described Alfacalcidol soft capsule, the content of the soft capsule by parts by weight such as
Under each component be prepared from：
43 parts of Alfacalcidol
19 parts of glycerine
29 parts of Macrogol 4000
16 parts of Macrogol 6000
15 parts of accelerator
51 parts of thickener
46 parts of antioxidant.
In the Alfacalcidol soft capsule of the present invention, adding glycerine, Macrogol 4000, Macrogol 6000 can effectively carry
For the stabilization and bioavilability of the soft capsule.
Further, the accelerator is selected from lauryl sodium sulfate, propane diols, sldium lauryl sulfate, castor oil and thin
One or more in lotus alcohol.
Preferably, the accelerator is that weight ratio is 7：6~10 lauryl sodium sulfate and menthol.More preferably
Ground, the accelerator is that weight ratio is 7：8 lauryl sodium sulfate and menthol, now, the accelerator makes active component
The compatibilities of Alfacalcidol and various auxiliary agents is best, the soft capsule is most stable, and can make the assimilation effect of active component most
It is good, bioavilability highest.
Further, the thickener is selected from sodium carboxymethylcellulose, sodium alginate, xanthans, cycloheptaamylose and carboxylic
One or more in methyl starch sodium.
Preferably, the thickener compares 7 for weight：5~11 sodium carboxymethylcellulose and sodium alginate, more there is choosing
Ground, the thickener compares 7 for weight：10 sodium carboxymethylcellulose and sodium alginate, now, soft capsule of the present invention is most steady
Fixed, preferably, the assimilation effect of active component is best, bioavilability highest for viscosity.
Further, the antioxidant is selected from BHT, anhydrous sodium sulfite, gallic acid, sorb
One or more in sour sodium and tocopherol.
Preferably, the antioxidant is that weight ratio is 1:1~1.5 gallic acid and tocopherol.It is highly preferred that institute
It is that weight ratio is 1 to state antioxidant:1.3 gallic acid and tocopherol, now, the stability of soft capsule of the present invention are best,
It is not easy to be oxidized.
It is a further object to provide the preparation method of described Alfacalcidol soft capsule, including following step
Suddenly：
1）Alfacalcidol, Macrogol 4000, Macrogol 6000 are crossed into 100~140 mesh sieves respectively, are well mixed,
Obtain powder standby；
2）Glycerine, accelerator, thickener, antioxidant are mixed, in 55~65 DEG C of stirrings, matrix is dissolved to obtain；
3）By step 1）Powder and step 2）Matrix mixing, at 75~85 DEG C mix, stir, dissolving, stirring 0.5
~1.5h obtains homogeneous content；
4）Content is put into reservoir, using rotating platen press, prepare soft capsule, Ran Houxi using automatic rotation rolling capsule machine
Ball, drying, packaging produce the Alfacalcidol soft capsule.
As preferred scheme, the preparation method of the Alfacalcidol soft capsule, including following steps：
1）Alfacalcidol, Macrogol 4000, Macrogol 6000 are crossed into 120 mesh sieves respectively, is well mixed, obtains powder
It is standby；
2）Glycerine, accelerator, thickener, antioxidant are mixed, in 60 DEG C of stirrings, matrix is dissolved to obtain；
3）By step 1）Powder and step 2）Matrix mixing, at 80 DEG C mix, stir, dissolving, stirring 1h obtain
Homogeneous content；
4）Content is put into reservoir, using rotating platen press, prepare soft capsule, Ran Houxi using automatic rotation rolling capsule machine
Ball, drying, packaging produce the Alfacalcidol soft capsule.
The capsule material of heretofore described Alfacalcidol soft capsule, may be selected existing known capsule material, as long as can realize
The soft capsule pressing process of content of the present invention prepares soft capsule.
Beneficial effects of the present invention：
1st, the present invention improves the content of active component in the formulation, reduces the dose of medicine；
2nd, by adding specific composition glycerine, Macrogol 4000, Macrogol 6000, the flexible glue is effectively increased
The stability and bioavilability of capsule；
3rd, the formulation of existing Alfacalcidol preparation is successfully changed, enables Alfacalcidol preferably by patient
Take absorption.
Embodiment
The preferred embodiments of the present invention are illustrated below, it will be appreciated that preferred embodiment described herein is only used
In the description and interpretation present invention, it is not intended to limit the present invention.
Embodiment 1：Alfacalcidol soft capsule
Alfacalcidol soft capsule described in the present embodiment, the content of the soft capsule is prepared by the following each component of weight
Form：
Alfacalcidol 43mg
Glycerine 19mg
Macrogol 4000 29mg
Macrogol 6000 16mg
Lauryl sodium sulfate 7mg
Menthol 8mg
Sodium carboxymethylcellulose 21mg
Sodium alginate 30mg
Gallic acid 20mg
Tocopherol 26mg.
The preparation method of Alfacalcidol soft capsule described in the present embodiment, including following steps：
1）Alfacalcidol, Macrogol 4000, Macrogol 6000 are crossed into 120 mesh sieves respectively, is well mixed, obtains powder
It is standby；
2）Glycerine, accelerator, thickener, antioxidant are mixed, in 60 DEG C of stirrings, matrix is dissolved to obtain；
3）By step 1）Powder and step 2）Matrix mixing, at 80 DEG C mix, stir, dissolving, stirring 1h obtain
Homogeneous content；
4）Content is put into reservoir, using rotating platen press, prepare soft capsule, Ran Houxi using automatic rotation rolling capsule machine
Ball, drying, packaging produce the Alfacalcidol soft capsule；When washing ball, drying, the soft capsule being pressed into is put in cold wind and shaped,
Temperature is 18 DEG C, and humidity is 50%；Through washing ball after sizing, temperature is 28 DEG C, and humidity is 50%, puts drying room, temperature is 40 DEG C, wet
Spend and dried for 50%, produced.
Embodiment 2：Alfacalcidol soft capsule
Alfacalcidol soft capsule described in the present embodiment, the content of the soft capsule is prepared by the following each component of weight
Form：
Alfacalcidol 40mg
Glycerine 17mg
Macrogol 4000 25mg
Macrogol 6000 13mg
Lauryl sodium sulfate 7mg
Menthol 6mg
Sodium carboxymethylcellulose 28mg
Sodium alginate 20mg
Gallic acid 17mg
Tocopherol 17mg.
The preparation method of Alfacalcidol soft capsule described in the present embodiment, including following steps：
1）Alfacalcidol, Macrogol 4000, Macrogol 6000 are crossed into 100 mesh sieves respectively, is well mixed, obtains powder
It is standby；
2）Glycerine, accelerator, thickener, antioxidant are mixed, in 65 DEG C of stirrings, matrix is dissolved to obtain；
3）By step 1）Powder and step 2）Matrix mixing, at 85 DEG C mix, stir, dissolving, stirring 1.5h obtain
To homogeneous content；
4）Content is put into reservoir, using rotating platen press, prepare soft capsule, Ran Houxi using automatic rotation rolling capsule machine
Ball, drying, packaging produce the Alfacalcidol soft capsule；When washing ball, drying, the soft capsule being pressed into is put in cold wind and shaped,
Temperature is 18 DEG C, and humidity is 50%；Through washing ball after sizing, temperature is 28 DEG C, and humidity is 50%, puts drying room, temperature is 40 DEG C, wet
Spend and dried for 50%, produced..
Embodiment 3：Alfacalcidol soft capsule
Alfacalcidol soft capsule described in the present embodiment, the content of the soft capsule is prepared by the following each component of weight
Form：
Alfacalcidol 45mg
Glycerine 20mg
Macrogol 4000 38mg
Macrogol 6000 18mg
Lauryl sodium sulfate 7mg
Menthol 10mg
Sodium carboxymethylcellulose 21mg
Sodium alginate 33mg
Gallic acid 20mg
Tocopherol 30mg.
The preparation method of Alfacalcidol soft capsule described in the present embodiment, including following steps：
1）Alfacalcidol, Macrogol 4000, Macrogol 6000 are crossed into 140 mesh sieves respectively, is well mixed, obtains powder
It is standby；
2）Glycerine, accelerator, thickener, antioxidant are mixed, in 55 DEG C of stirrings, matrix is dissolved to obtain；
3）By step 1）Powder and step 2）Matrix mixing, at 75 DEG C mix, stir, dissolving, stirring 0.5h obtain
To homogeneous content；
4）Content is put into reservoir, using rotating platen press, prepare soft capsule, Ran Houxi using automatic rotation rolling capsule machine
Ball, drying, packaging produce the Alfacalcidol soft capsule；When washing ball, drying, the soft capsule being pressed into is put in cold wind and shaped,
Temperature is 18 DEG C, and humidity is 50%；Through washing ball after sizing, temperature is 28 DEG C, and humidity is 50%, puts drying room, temperature is 40 DEG C, wet
Spend and dried for 50%, produced..
Embodiment 4：Alfacalcidol soft capsule
Alfacalcidol soft capsule described in the present embodiment, the content of the soft capsule is prepared by the following each component of weight
Form：
Alfacalcidol 35mg
Glycerine 15mg
Macrogol 4000 20mg
Macrogol 6000 45mg
Propane diols 10mg
Xanthans 10mg
DBPC 2,6 ditertiary butyl p cresol 30mg.
The preparation method be the same as Example 1 of Alfacalcidol soft capsule described in the present embodiment.
Embodiment 5：Alfacalcidol soft capsule
Alfacalcidol soft capsule described in the present embodiment, the content of the soft capsule is prepared by the following each component of weight
Form：
Alfacalcidol 50mg
Glycerine 20mg
Macrogol 4000 40mg
Macrogol 6000 20mg
Sldium lauryl sulfate 10mg
Castor oil 10mg
Cycloheptaamylose 27mg
Sodium carboxymethyl starch 30mg
Anhydrous sodium sulfite 30mg
Sodium sorbate 30mg.
The preparation method be the same as Example 1 of Alfacalcidol soft capsule described in the present embodiment.
Reference examples 1：Alfacalcidol soft capsule
Alfacalcidol soft capsule described in the present embodiment, the content of the soft capsule is prepared by the following each component of weight
Form：
Alfacalcidol 43mg
Lauryl sodium sulfate 7mg
Menthol 8mg
Sodium carboxymethylcellulose 21mg
Sodium alginate 30mg
Gallic acid 20mg
Tocopherol 23mg.
The preparation method be the same as Example 1 of Alfacalcidol soft capsule described in the present embodiment.
Reference examples 2：Alfacalcidol soft capsule
Alfacalcidol soft capsule described in the present embodiment, the content of the soft capsule is prepared by the following each component of weight
Form：
Alfacalcidol 43mg
Glycerine 19mg
Macrogol 4000 29mg
Macrogol 6000 16mg
The preparation method be the same as Example 1 of Alfacalcidol soft capsule described in the present embodiment.
Experimental example 1：Stability test
1.1 test specimens：Sample 1-5 is Alfacalcidol soft capsule prepared by embodiment of the present invention 1-5；Reference substance 1-2
The Alfacalcidol soft capsule prepared for reference examples 1-2；Reference substance 3 is the Alfacalcidol glue of embodiment 1 in CN103110606
Capsule.
1.2 test methods：At room temperature, 65% time placement of relative humidity 24 months, takes when 0,4,8,12 and 24 months
Sample uses HPLC, and assay is carried out using internal standard method（The percentage of measured amount and labelled amount）.
1.3 experimental conditions：Ultraviolet absorption detector Detection wavelength 265nm；Silica gel is filler, and theoretical cam curve presses Ah method
Ostelin peak, which is calculated, should be not less than 2000；Mobile phase：Ethyl acetate petroleum ether（60 ~ 90 DEG C) chloroform=42 44 14；Post
Temperature：Room temperature.
1.4 Alfacalcidol assay result of the tests are shown in Table 1.
The Alfacalcidol assay result of the test of table 1（%）
It can be seen from table 1, compared with reference substance 1-3, the Alfacalcidol soft capsule table prepared by embodiment of the present invention 1-5
Reveal and its excellent stability, the Alfacalcidol soft capsule that wherein prepared by embodiment 1 is most stable.
Experimental example 2：Bioavailability study
2.1 test specimens：With experimental example 1.
2.2 test methods：Respectively to 8 beasle dogs（It is male）It is administered orally, they is fed with sample respectively
1-5, reference substance 1-3 preparation, dosage are 15.0 μ g/ only（In terms of Alfacalcidol）.The interval time being administered every time is 7
My god.After administration 3 times, blood sample is gathered under different time, and carry out the maximum haemoconcentration of Alfacalcidol（Cmax）With biology profit
Expenditure（AUC0→0-48）Calculating.Acquisition time be 0,0.5,1,2,4,6,8,12,24,32,48h.
2.3 result of the tests
Average result to determining gained in 48h after 8 beasle dog administrations, is shown in Table 2.
Table 2, bioavilability compare（15.0 μ g, are administered 3 times）
It can be seen from table 2, compared with reference substance 1-3, the Alfacalcidol that embodiment of the present invention 1-5 prepares is taken soft
The Alfacalcidol haemoconcentration of capsule is larger, bioavilability is excellent；Wherein, take that embodiment 1 prepares Ah
The Alfacalcidol haemoconcentration maximum of the ossified alcohol soft capasule of method, bioavilability highest.
Finally it should be noted that：The preferred embodiments of the present invention are the foregoing is only, are not intended to limit the invention,
Although the present invention is described in detail with reference to the foregoing embodiments, for a person skilled in the art, it still may be used
To be modified to the technical scheme described in foregoing embodiments, or to which part technical characteristic progress equivalent.
Within the spirit and principles of the invention, any modifications, equivalent substitutions and improvements made etc., should be included in the present invention's
Within protection domain.
Claims (12)
1. a kind of Alfacalcidol soft capsule, it is characterised in that：The content of the soft capsule is by the following each component of parts by weight
It is prepared from：
35~50 parts of Alfacalcidol
15~20 parts of glycerine
20~40 parts of Macrogol 4000
10~20 parts of Macrogol 6000
10~20 parts of accelerator
45~57 parts of thickener
30~60 parts of antioxidant,
One kind in lauryl sodium sulfate, propane diols, sldium lauryl sulfate, castor oil and menthol of the accelerator or
It is several.
2. Alfacalcidol soft capsule according to claim 1, it is characterised in that：The content of the soft capsule is by weight
The following each component of part is prepared from：
40~45 parts of Alfacalcidol
17~20 parts of glycerine
25~38 parts of Macrogol 4000
13~18 parts of Macrogol 6000
13~17 parts of accelerator
48~54 parts of thickener
34~50 parts of antioxidant.
3. Alfacalcidol soft capsule according to claim 2, it is characterised in that：The content of the soft capsule is by weight
The following each component of part is prepared from：
43 parts of Alfacalcidol
19 parts of glycerine
29 parts of Macrogol 4000
16 parts of Macrogol 6000
15 parts of accelerator
51 parts of thickener
46 parts of antioxidant.
4. Alfacalcidol soft capsule according to claim 1, it is characterised in that：The accelerator is that weight ratio is 7：6
~10 lauryl sodium sulfate and menthol.
5. Alfacalcidol soft capsule according to claim 4, it is characterised in that：The accelerator is that preferred weight ratio is
7：8 lauryl sodium sulfate and menthol.
6. Alfacalcidol soft capsule according to any one of claim 1 to 3, it is characterised in that：The thickener choosing
One or more from sodium carboxymethylcellulose, sodium alginate, xanthans, cycloheptaamylose and sodium carboxymethyl starch.
7. Alfacalcidol soft capsule according to claim 6, it is characterised in that：The thickener compares 7 for weight：5~
11 sodium carboxymethylcellulose and sodium alginate.
8. Alfacalcidol soft capsule according to claim 7, it is characterised in that：The thickener is that preferred weight ratio is
7：10 sodium carboxymethylcellulose and sodium alginate.
9. Alfacalcidol soft capsule according to any one of claim 1 to 3, it is characterised in that：The antioxidant choosing
One or more from DBPC 2,6 ditertiary butyl p cresol, anhydrous sodium sulfite, gallic acid, sodium sorbate and tocopherol.
10. Alfacalcidol soft capsule according to claim 9, it is characterised in that：The antioxidant is that weight ratio is 1:1
~1.5 gallic acid and tocopherol.
11. Alfacalcidol soft capsule according to claim 10, it is characterised in that：The antioxidant is preferred weight ratio
For 1:1.3 gallic acid and tocopherol.
12. the preparation method of the Alfacalcidol soft capsule any one of claim 1 to 9, it is characterised in that：Including with
Under each step：
1）Alfacalcidol, Macrogol 4000, Macrogol 6000 are crossed into 100~140 mesh sieves respectively, is well mixed, obtains powder
Material is standby；
2）Glycerine, accelerator, thickener, antioxidant are mixed, in 55~65 DEG C of stirrings, matrix is dissolved to obtain；
3）By step 1）Powder and step 2）Matrix mixing, at 75~85 DEG C mix, stir, dissolving, stirring 0.5~
1.5h obtains homogeneous content；
4）Content is put into reservoir, using rotating platen press, preparing soft capsule using automatic rotation rolling capsule machine, then wash ball,
Dry, packaging produces the Alfacalcidol soft capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510191507.4A CN104800187B (en) | 2015-04-22 | 2015-04-22 | A kind of Alfacalcidol soft capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510191507.4A CN104800187B (en) | 2015-04-22 | 2015-04-22 | A kind of Alfacalcidol soft capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104800187A CN104800187A (en) | 2015-07-29 |
| CN104800187B true CN104800187B (en) | 2017-07-14 |
Family
ID=53685687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510191507.4A Active CN104800187B (en) | 2015-04-22 | 2015-04-22 | A kind of Alfacalcidol soft capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104800187B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109248156A (en) * | 2018-11-27 | 2019-01-22 | 正大制药（青岛）有限公司 | A kind of paricalcitol soft capsule |
| CN109481414B (en) * | 2018-11-27 | 2021-05-04 | 正大制药（青岛）有限公司 | Adeladol soft capsule |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1371281A (en) * | 1999-08-31 | 2002-09-25 | 中外制药株式会社 | Soft capsules |
| CN102939078A (en) * | 2010-06-11 | 2013-02-20 | 利奥制药有限公司 | A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100438254B1 (en) * | 2001-03-29 | 2004-07-02 | 아이큐어 주식회사 | Matrix form of preparation for transdermal administration of vitamin d analog |
| US20050209203A1 (en) * | 2003-07-30 | 2005-09-22 | Jin Tian | Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease |
-
2015
- 2015-04-22 CN CN201510191507.4A patent/CN104800187B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1371281A (en) * | 1999-08-31 | 2002-09-25 | 中外制药株式会社 | Soft capsules |
| CN102939078A (en) * | 2010-06-11 | 2013-02-20 | 利奥制药有限公司 | A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid |
Non-Patent Citations (2)
| Title |
|---|
| 充液胶囊处方筛选研究进展;李亚冰，等;《医药导报》;20110731;第30卷(第7期);第915-918页，尤其是第916页右栏第3段 * |
| 软胶囊剂稳定性研究进展;黄敏，等;《中国医药工业杂志》;20001231;第31卷(第3期);第137-140页，尤其是第139页左栏最后一段至右栏第一段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104800187A (en) | 2015-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102811718A (en) | Pharmaceutical composition for improving solubility of prasugrel and its preparation method | |
| WO2007056424A2 (en) | Controlled-release emulsion compositions | |
| CN1148224C (en) | Cyclosporin containing composition and process for preparation | |
| WO2017116190A1 (en) | Pharmaceutical composition comprising dutasteride and propylene glycol monolaurate and preparation method of the same | |
| CN100341577C (en) | Transdermal absorption preparation | |
| CN104800187B (en) | A kind of Alfacalcidol soft capsule and preparation method thereof | |
| CN103142532B (en) | Ginkgolide osmotic pump tablet and preparation method thereof | |
| TW200840596A (en) | Microemulsion dosage forms of valsartan and methods of making the same | |
| CN102470121B (en) | Pharmaceutical compositions comprising dronedarone | |
| WO1992016237A1 (en) | Composition for relieving skin irritation and external preparation for percutaneous adminstration containing the same | |
| CN103096877B (en) | The new formulation of 14 epimerism analogs of vitamin D | |
| CN106606486A (en) | Bilastine tablet and preparation method thereof | |
| CN107362151A (en) | A kind of calcitriol liquid hard capsule and preparation method thereof, application | |
| CN102872002B (en) | Hydroxysafflor yellow A oil solution and preparation method and application thereof | |
| CN111214453A (en) | Alfacalcidol soft capsule and preparation method thereof | |
| CN106309395A (en) | Tacrolimus sustained-release tablets and preparation method thereof | |
| CN102302470B (en) | Nitrendipine soft capsule | |
| CN103860496A (en) | Bazedoxifene acetate dispersing tablet and preparation method thereof | |
| EP2255786A1 (en) | Self-microemulsifying mitotane composition | |
| CN107773544A (en) | A kind of preparation method of olmesartan medoxomil tablet | |
| CN112472681A (en) | Impermeable coating premixing technology for calcitriol soft capsule | |
| CN102697764A (en) | Enteric solid preparation containing phenethyl isothiocyanate | |
| CN101647782A (en) | Vinpocetine oral administration self-microemulsifying pellet as well as preparation method and application thereof | |
| CN102274274B (en) | Self-microemulsifiable kudzu root flavone oral micro-pill composition and preparation method thereof | |
| CN101416954A (en) | Nitrendipine self-emulsification soft capsules and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 266000 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong Patentee after: CP PHARMACEUTICAL (QINGDAO) Co.,Ltd. Address before: 266000 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong Patentee before: Qingdao Zhengda Haier Pharmaceutical Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: No.3601 Tuanjie Road, Qingdao Economic and Technological Development Zone, Shandong Province 266426 Patentee after: Qingdao Guoxin Pharmaceutical Co.,Ltd. Country or region after: China Address before: No. 3601 Tuanjie Road, Qingdao Economic and Technological Development Zone, Shandong Province Patentee before: CP PHARMACEUTICAL (QINGDAO) Co.,Ltd. Country or region before: China |